Ur Medicine Central Laboratory
Ur Medicine Central Laboratory is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
Sponsor Kite Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- Enrollment was geographically concentrated in the United States (66 participants), with 10 enrolled in France, 6 in Canada, 5 in Spain, 3 each in Italy and Poland, and 1 each in the Czech Republic and Germany.
- No global study interruptions or restarts were reported.
- The protocol was amended eight times during the study.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)
Sponsor Kite Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A PHASE 2 MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN SUBJECTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (INHL)
Sponsor Kite Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Ur Medicine Central Laboratory?
The 2026-10-09 snapshot links Ur Medicine Central Laboratory to 3 distinct CTIS trials. Recorded services include Laboratory services, Bone Marrow analysis, provides storage of and coordination of sample shipment, Co-ordination of Antibody and RCR testing. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Ur Medicine Central Laboratory?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Ur Medicine Central Laboratory conducted?
The linked trials record locations in 7 countries, including France, Germany, Spain, Czechia, Italy. These are trial locations, not confirmed office locations or countries where Ur Medicine Central Laboratory delivered services.
What can this page tell me about Ur Medicine Central Laboratory's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Ur Medicine Central Laboratory. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- UR Medicine Central Laboratory
- Ur Medicine Central Laboratory